Related Experiment Video
Updated: May 5, 2026
05:29
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
2.8K
Unlocking Glioblastoma Vulnerabilities with CRISPR-Based Genetic Screening
Yitong Fang1,2, Xing Li1,2, Ruilin Tian1,2
1Department of Medical Neuroscience, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
International Journal of Molecular Sciences
|June 19, 2024
Summary
CRISPR genetic screening advances GBM research by identifying key genes for tumor growth and therapy resistance. This review highlights recent progress and future directions for treating glioblastoma.
Area of Science:
- Neuro-oncology
- Genetics
- Molecular Biology
Background:
- Glioblastoma (GBM) is a highly aggressive brain tumor with poor patient prognosis.
- Limited treatment efficacy is often due to tumor resistance.
- CRISPR-based genetic screening offers a powerful approach to understand GBM biology.
Purpose of the Study:
- To review recent advancements in CRISPR-based genetic screening for glioblastoma.
- To highlight the application of these screening methods in identifying GBM therapeutic targets.
- To discuss challenges and future prospects of CRISPR screening in GBM research.
Main Methods:
- Review of current literature on CRISPR-based genetic screening techniques.
- Analysis of studies applying CRISPR screening to glioblastoma models.
- Synthesis of findings related to gene discovery and therapeutic target identification.
Main Results:
- CRISPR screening has successfully identified genes critical for GBM progression.
- These methods have uncovered genetic factors influencing resistance to various therapies.
- New potential therapeutic targets for glioblastoma have been revealed.
Conclusions:
- CRISPR-based genetic screening is a vital tool for advancing glioblastoma research.
- Continued development and application of these methods promise improved understanding and treatment of GBM.
- Addressing current challenges will further enhance the utility of CRISPR screening in neuro-oncology.
